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Interleukin-13 Increases Podocyte Apoptosis in Cultured 
Human Podocytes
Purpose: Podocytes are important architectures that maintain the crucial roles 
of glomerular filtration barrier functions. Despite this structural importance, how-
ever, the mechanisms of the changes in podocytes that can be an important pa-
thogenesis of minimal change nephrotic syndrome (MCNS) are not clear yet. The 
aim of this study was to investigate whether apoptosis is induced by interleukin 
(IL)-13 in cultured human podocytes.
Methods: Human podocytes were treated with different IL-13 doses and apoptotic 
cells were analyzed using terminal deoxynucleotidyl transferase dUTP nick-end 
labeling (TUNEL assay) and fluorescence-activated cell sorting (FACS).
Results: The IL-13 increased the number of TUNEL-positive cells in a dose-depen-
dent manner at 6 and 18 hours (P<0.05 and P<0.05, respectively). The apop tosis 
rate was appeared to be increased slightly in the IL-13-stimulated podocytes (8.63 
%, 13.02%, and 14.46%; 3, 10 and 30 ng/mL, respectively) than in the control cells 
(7.66%) at 12 hours by FACS assay.  
Conclusion: Our study revealed that IL-13 expression may increase podocyte 
apoptosis. Blocking the IL-13 signal pathway can potentially play an important 
role in regulating the apoptosis of podocytes.
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Introduction
Minimal change nephrotic syndrome (MCNS) accounts for 84.5% of idio­
pathic nephrotic syndrome (INS) in children, and 10 to 25% of INS in adults1, 
2). About 80–90% of children with childhood INS are steroid­sensitive ne­
phrotic syndrome (SSRS) and around 60% of MCNS children show SSRS3,4). 
Even though initial response rate to steroids is 90% to 95%,  20–60% of SSRS 
children relapse and about 60–90% of them will have five or more relapses 
with increased morbidity4,5). Resistance to therapy, also called as steroid­re­
sistant nephrotic syndrome (SRNS), occurs in 50% of focal segmental glo­
merulosclerosis (FSGS) and 10% of MCNS often progress to renal failure re­
quiring dialysis and transplantation despite various immunosuppressive 
treatments6­9). 
MCNS is composed of two important pathologic features: 1) absence of 
glomerular immune complex deposition and 2) foot process effacement (podo­
cytes seem to be fused together a f lattened morphology)8). Foot process 
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effacement is closely related the changes in the selective 
barrier in the slit diaphragm, which is composed of a 
number of proteins: nephrin, P­cadherin, CD2­asso ciated 
protein, zona occludens (ZO)­1, Fat cad herin, podo cin, 
and Neph110,11). 
Interleukin (IL)­13 is a kind of T cell­derived cytokine12). 
It is also reported to be an important cytokine in MCNS 
and we previously reported that IL­13 may increase podo­
cyte permeability through the modulation of ZO­113,14). 
How ever, there have been no reports about podocyte apop­
tosis related to IL­13. The aim of this study was to investi­
gate whether apoptosis is induced by IL­13 in cultured 
human podocytes.
Materials and methods
1. Cell culture of human podocytes
Human conditionally immortalized podocytes (AB8/23) 
was cloned from human glomerular cultures. Dr. Moin A. 
Saleem (University of Bristol, Bristol, UK) cha racterized 
and generously provided them. Then human podocytes 
were maintained in RPMI 1640 (WelGENE Inc., Daegu, 
South Korea) supplemented with 10% heat­inacti vated 
fetal bovine serum (FBS), Insulin­Transferrin­Sele nium­
Pyruvate Supplement (ITSP; WelGENE Inc.), and anti­
biotics. Once every 2 days, fresh media was supplied. 
Cells were cultivated at 33℃ (permissive conditions) in 
a culture medium supplemented with human recombinant 
ITSP to induce expression of temperature­sensitive large T 
antigens and to stimulate human podocyte proliferation. 
To induce differentiation, podocytes were maintained at 
37℃ (non­permissive conditions) for at least 2 weeks, and 
for subcultures, 0.05% trypsin was used to detach cells from 
the culture dishes.
2. IL-13 treatment conditions 
To imitate MCNS­like conditions, cells were incubated 
with various concentrations of IL­13 (Peprotech Inc., Rocky 
Hill, NJ, USA) during the indicated time periods (6, 12 and 
18 hours). IL­13 was administered with various concentra­
tions (3, 10, 30, and 100 ng/mL) into 0.5% RPMI at 37℃.
3. Measurement of apoptosis 
1) Terminal deoxynucleotidyl transferase dUTP nickend 
     labeling (TUNEL assay)
TUNEL assay was done using In situ Cell Death Detec­
tion Kit (Roche Molecular Biochemicals, Mannheim, 
Germany). Podocytes that were grown on type I collagen­
coated glass coverslips incubated for 24 hours were fixed 
in 4% paraformaldehyde for 1 hour, followed by permea­
bilization with 0.1% Triton X­100 for 10 minutes at room 
temperature. After coverslips were mounted in mountant, 
the samples were immediately evaluated using a fluores­
cence microscope. The TUNEL index (apoptotic podocytes) 
was determined by counting the positively and negatively 
stained cells in each of 10 fields of vision. Cell numbers 
were converted to percent apoptotic cells for statistical 
analysis. 
2) Fluorescence­activated cell sorting (FACS) 
We conducted a flow cytometric analysis to elucidate 
whether IL­13 has apoptotic effects on podocytes. The ap­
optotic rate was calculated by a single­color flow cytometric 
analysis depending upon the IL­13 concentrations (control, 
3, 10, and 30 ng/mL) and apoptotic hours (6 and 12 hours). 
Equal numbers of podocytes were cultivated on 6 cm tissue 
culture plates in medium. After IL­13 modulation, cell cul­
ture medium was collected and saved. Cells were washed 
once with 1.5 ml of phosphate­buffered saline (PBS). PBS 
used for washing was combined with the saved culture 
medium. Podocyte cells were analyzed with the Mofro 
Astrios flow cytometer (FACSCalibur­S System, Becton 
Dickinson Biosciences, San Jose, CA, USA). The number 
of apoptotic cells was calculated by multiplying the percen­
tages of apoptosis and necrosis as determined by FACS.
4. Statistical analysis
Results are described as mean ± standard deviation, as 
appropriate under different conditions. Statistical signifi­
cance was evaluated by the non­parametric Kruskal­Wallis 
analysis or Student’s t­test. P­values <0.05 were considered 
significant.
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Results 
1. Apoptotic rate on TUNEL assay
Apoptosis is a programmed cell death which results the 
series of events including alterations in the plasma mem­
brane, activation of enzymes15). DNA fragmentation can 
be detected in terminal stages of apoptosis by labeling with 
fluorescent tagged nucleotides through a technique called 
as TUNEL16). Apoptotic podocytes were identified as 
TUNEL positive cells while the normal cells lacked nuclear 
staining. IL­13 increased the number of TUNEL­positive 
cells in a dose­dependent manner at 6 and 18 hours (P<0.05 
and P<0.05, respectively) (Fig. 1, 2). 
2. FACS assay for apoptosis
The apoptotic effects of IL­13 on podocytes were an­
alyzed by FACS. There was no significant difference in the 
rate of apoptosis in controls and podocytes stimulated by 
different concentrations (3, 10 and 30 ng/mL) at 6 hours 
(9.73% vs. 13.89%, 12.52%, 10.83%, respectively, Fig. 3); at 
12 hours, however, the rate of apoptosis was slightly in­
creased in IL­13 stimulated podocytes (8.63%, 13.02%, 
14.46%) than control cells (7.66%, Fig. 4).
Discussion
Podocytes are important structures which maintain the 
crucial roles of glomerular filtration barrier functions9,10). 
In 2007, Lai et al. suggested that IL­13 overexpression could 
lead to podocyte injury with downregulation of proteins 
such as nephrin, podocin, and dystroglycan and a concur­
rent upregulation of B7­1 in MCNS induced rat17). After 
that, our previous studies reported that IL­13 was involved 
in the changes of ZO­1 proteins in podocytes which could 
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Fig. 1. TUNEL assay for apoptosis (6 hours). IL-13 increased the 
number of TUNEL-positive cell in a dose-dependent manner at 6 
hours (*P<0.05). IL-13, interleukin-13; TUNEL, terminal deoxynu-
cleotidy1 transferase dUTP nickend labeling.
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Fig. 2. TUNEL assay for apoptosis (18 hours). IL-13 increased the 
number of TUNEL-positive cell in a dose-dependent manner at 
18 hours (*P<0.05). IL-13, inter leukin-13; TUNEL, terminal deoxy-
nucleotidy1 transferase dUTP nickend labeling.
Control IL-13 3 ng IL-13 10 ng IL-13 30 ng 
Fig. 3. FACS assay for apoptosis (6 hours). FACS, fluorescence-activated cell sorting; IL-13, interleukin-13.
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be a pathogenesis of MCNS14,18). Other recent studies have 
shown that increase in IL­13 production was to cause fre­
quent relapse in SSNS13,19). In this point of view, the aim of 
this study was to identify whether apoptosis in podocytes 
could be induced by IL­13.
There have been two suspected modes of podocyte apop­
tosis: 1) intrinsic apoptosis and 2) extrinsic apoptosis. In­
trinsic apoptosis is related to a mitochondrion­centered 
control mechanism20). On the other hand, extrinsic apop­
tosis is a caspase­dependent cell death related to activation 
of the caspase­9­caspase­3 cascade21,22). Generally, caspase­ 
3 is known as a key mediator as a leading enzyme in cell 
death23). Pro­caspase­3 is usually processed by autoproteo­
lytic cleavage and activated caspase­3 has been identified 
that are related to mitochondrial cytochrome c release and 
caspase­9 function24,25). Manna et al. reported that IL­13 is 
a potent inhibitor of TNF­mediated activation and caspase­ 
3 related apoptosis in 199826). In contrast, recent studies 
show IL­13 induces apoptotic pathways of cell death in head 
and neck cancer models27,28). 
IL­13 has been known as a causative factor of cell apop­
tosis in several previous studies. Borowski et al. reported 
that IL­13 can be a mediator on lung epithelial cells as an 
apoptotic effector, which leads to loss of functional airway 
tissue and finally results in asthma29). 
Several studies have already reported about the role of 
IL­13 as a pathogen in other cells and diseases other than 
podocytes. Heller et al. found that IL­13 can effect on in­
testinal epithelial barrier dysfunction and eventually cause 
ulcerative colitis30). For this explanation, signal transduc­
tion qualities mediated by the respective receptors for IL‐ 
13 may result in distinct patterns of transcription regula­
tion, ultimately explaining the unique role of IL‐13 in 
asthma pathogenesis. JAK/STAT activation pathway can 
be an optional mechanism to explain these results31). This 
pathway is induced by the IL‐13 receptor complex and then 
eventually causes cell apoptosis and destruction of cell junc­
tions31). Exact mechanisms of these mediators, however, 
are unclear. 
In this study, it is implicated that IL­13 can induce po­
docyte apoptosis. Our results and previous studies above 
indicate that IL­13 can be related to extrinsic apop tosis of 
podocyte, blocking this signal pathway. 
 Our study has several limitations: First, we were unable 
to reveal all exact mechanism of IL­13 in podocytes. Second, 
we did not include treatment attempt to prevent podocyte 
apoptosis into our experiments. Despite these limitations, 
our study is the first attempt to demonstrate the IL­13 as a 
key marker and potential treatment target to prevent 
changes related to cell death in human podocytes. 
In conclusion, our preliminary results suggest that IL­13 
may increase podocyte apoptosis.  Such alterations can be 
relevant to the foot process changes in podocytes related 
to pathogenesis of proteinuria in the IL­13­induced MCNS 
model. Further studies about the methods of suppression 
of IL­13 are needed, and it will be noteworthy to explore 
whether IL­13 modulation can modify podocytes from 
MCNS. 
Control IL-13 3 ng IL-13 10 ng IL-13 30 ng 
Fig. 4. FACS assay for apoptosis (12 hours). FACS, fluorescence-activated cell sorting; IL-13, interleukin-13.
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